CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 (World NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-phase business targeted on exceptional conditions that transforms genuine-environment scientific and genetic info into actionable details for sufferers, medical professionals, and pharmaceutical firms, nowadays presented an update on its company development and reported its monetary success for the three and nine months ended September 30, 2020.
- Revenues amplified 212% compared to Q3 2019, driven by the ongoing growth of our COVID-19 testing supplying
- Amplified 2020 comprehensive-calendar year earnings assistance to more than €100 million
- Continued advancement of new pharma partnerships, with 12 new specials signed and a strong recovery anticipated in 2021
- Growth of professional COVID-19 testing, which now features antigen testing
- Introduced leadership transition and appointment of Dr. Andrin Oswald as Main Executive Officer to help the up coming phase of the Company’s advancement
Andrin Oswald, M.D., Main Govt Officer at CENTOGENE, stated, “I am excited to have joined CENTOGENE at these types of an vital phase in the Company’s evolution. Even though I have only been with CENTOGENE for a number of months, it is obvious to me that our whole staff is concentrated on achieving a frequent goal of serving to rare disorder people all-around the earth. We imagine that our mission has the possible to noticeably lower the load of scarce ailments – and presents an fascinating value generation chance for our stakeholders at the very same time. Leveraging much more than 20 a long time of qualified expertise across the existence sciences, which include my time at Novartis and the Invoice and Melinda Gates Foundation, I am seeking ahead to helping more scale and speed up CENTOGENE’s advancement as a chief in the rare illness space.”
Richard Stoffelen, Main Monetary Officer at CENTOGENE, said, “During the 3rd quarter, we noticed a major increase in our revenues, yr-more than-12 months, driven by our ability to leverage our main competency in exact health care diagnoses to pivot rapidly and give answers to support address the COVID-19 pandemic. As we technique the stop of what has been an unparalleled yr, I would like to thank the overall CENTOGENE team once far more for their flexibility and unwavering motivation.”
A Stable Foundation for 2021
CENTOGENE has leveraged its core competency of giving precise healthcare diagnoses, as very well as its infrastructure, to assist stop even more outbreaks of SARS-CoV-2 (COVID-19) during 2020. As section of this initiative, CENTOGENE has turn out to be one of the most significant COVID-tests organizations in Europe and made a pioneering and primary purpose in giving screening services at airports. The constructive economic contribution from COVID-19 tests will empower the Organization to make strategic investments to additional solidify its foremost position in the scarce disorder house. The variety of Pharma partnership conversations have also ongoing to raise considering that Q2 2020, positioning CENTOGENE for further development in 2021.
Further information on the Company’s Q3 2020 Earnings, including the management’s dialogue and examination of money issue and benefits of operations, can be located by viewing EDGAR on the SEC web page at www.sec.gov, as nicely as the Trader Relations web site of the Company’s website at http://investors.centogene.com.
CENTOGENE engages in diagnosis and research about exceptional illnesses reworking genuine-environment scientific and genetic facts into actionable data for patients, physicians, and pharmaceutical firms. Our aim is to provide rationality to therapy conclusions and to speed up the advancement of new orphan medicine by employing our in depth scarce sickness know-how, which includes epidemiological and medical information, as well as progressive biomarkers. CENTOGENE has designed a worldwide proprietary exceptional condition platform dependent on our true-environment facts repository with above 3.6 billion weighted details points from somewhere around 595,000 clients representing about 120 distinctive nations around the world as of September 30, 2020.
The Company’s platform involves epidemiologic, phenotypic, and genetic facts that reflects a international populace, and also a biobank of these patients’ blood samples. CENTOGENE thinks this represents the only system that comprehensively analyzes multi-stage details to make improvements to the comprehending of unusual hereditary diseases, which can support in the identification of sufferers and boost our pharmaceutical partners’ capability to convey orphan drugs to the marketplace. As of September 30, 2020, the Business collaborated with over 40 pharmaceutical companions covering more than 45 various uncommon diseases.
Important Detect and Disclaimer
This push launch contains statements that constitute “forward-wanting statements” as that term is defined in the United States Non-public Securities Litigation Reform Act of 1995, which includes statements that categorical the Company’s opinions, anticipations, beliefs, strategies, goals, assumptions, or projections with regards to potential activities or foreseeable future final results, in contrast with statements that replicate historic facts. Illustrations contain discussion of our procedures, financing programs, progress opportunities, and current market expansion. In some situations, you can detect this sort of ahead-seeking statements by terminology these types of as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project” or “expect,” “may,” “will,” “would,” “could,” or “should,” the damaging of these conditions or equivalent expressions. Ahead-wanting statements are centered on management’s present beliefs and assumptions and on information and facts at present obtainable to the Organization. Nevertheless, these ahead-looking statements are not a promise of our effectiveness, and you should not area undue reliance on these statements. Ahead-on the lookout statements are matter to several threats, uncertainties, and other variable situation, this kind of as adverse around the world financial disorders and ongoing instability and volatility in the globally monetary markets, the outcomes of the COVID-19 pandemic on our organization and results of operations, feasible changes in current and proposed legislation, rules and govern-psychological insurance policies, pressures from increasing competitiveness and consolidation in our field, the expense and uncertainty of regulatory approval, which includes from the U.S. Food stuff and Drug Administration, our reliance on third parties and collaboration partners, together with our skill to manage growth and enter into new client associations, our dependency on the rare disorder industry, our means to manage worldwide enlargement, our reliance on critical personnel, our reliance on intellectual house security, fluctuations of our working effects owing to the outcome of exchange costs, or other elements. This kind of hazards and uncertainties may possibly bring about the statements to be inaccurate and visitors are cautioned not to place undue reliance on this sort of statements. Several of these pitfalls are outside of the Company’s command and could result in its actual final results to differ materially from these it considered would come about. The forward-wanting statements included in this press launch are designed only as of the date hereof. The Organization does not undertake, and exclusively declines, any obligation to update any these kinds of statements or to publicly announce the effects of any revisions to any these statements to replicate long run functions or developments, apart from as essential by regulation.
For even further info, be sure to refer to the Possibility Aspects section in our Once-a-year Report for the yr ended December 31, 2019, on Variety 20-F submitted with the SEC on April 23, 2020, Kind 6-K containing our economical benefits for the 3 months ended March 31, 2020, furnished to the SEC on June 15, 2020, Kind 6-K made up of our economical success for the three and 9 months finished September 30, 2020, furnished to the SEC on December 16, 2020, and other existing reports and files furnished to or submitted with the U.S. Securities and Trade Commission (SEC). You may get these documents by traveling to EDGAR on the SEC website at www.sec.gov.